Идентификационный номер :     Пароль:    

Забыли пароль? - нажмите здесь
У вас нет идентификационного номера? - зарегистрируйтесь

Новые методы лечения расстройств аутичного спектра: систематизированный обзор


1. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Baird G, Charman T, Baron-Cohen S, et al. A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2000;39:694-702.
3. Bertrand J, Mars A, Boyle C, et al. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics. 2001;108:1155-1161.
4. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA. 2001;285:3093-3099.
5. Rice C. Prevalence of autism spectrum disorders— autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR. 2007;56:12-28.
6. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113:e472-e486.
7. Green VA, Pituch KA, Itchon J, et al. Internet survey of treatments used by parents of children with autism. Res Dev Disabil. 2006;27:70-84.
8. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among
individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33:527-534.
9. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2005;15:671-681.
10. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Prevalence and patterns of use of psychoactive
medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002;12:311-321.
11. US Food and Drug Administration. FDA approves the first drug to treat irritability associated with autism, risperdal 2006. Available at: http://www.fda.gov/bbs/topics/news/2006/new01485.html. Accessed May 6, 2009.
12. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9:343-354.
13. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999;52:782-785.
14. Hyman SL, Levy SE. Introduction: novel therapies in developmental disabilities—hope, reason, and evidence. Ment Retard Dev Disabil Res Rev. 2005;11:107-109.
15. American Academy of Pediatrics. Counseling families who choose complementary and alternative
medicine for their child with chronic illness or disability. Committee on Children With Disabilities. Pediatrics. 2001;107:598-601.
16. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. 2001.
Available at: http://www.cebm.net/levels_of_evidence. asp. Accessed May 6, 2009.
17. Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000;21:347-350.
18. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658-665.
19. Defining and describing complementary and alternative medicine. Panel on Definition and Description,
CAM Research Methodology Conference, April 1995. Altern Ther Health Med. 1997;3:49-57.
20. Loman DG. The use of complementary and alternative health care practices among children. J Pediatr
Health Care. 2003;17:58-63.
21. Sanders H, Davis MF, Duncan B, et al. Use of complementary and alternative medical therapies among
children with special health care needs in southern Arizona. Pediatrics. 2003;111:584-587.
22. Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord. 2006;36:901-909.
23. Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord. 2007;37:628-636.
24. Wong VC. Use of complementary and alternative medicine (CAM) in autism spectrum disorder (ASD):
comparison of Chinese and Western culture (part A). J Autism Dev Disord. 2009;39:454-463.
25. Autism Research Institute. Parent ratings of behavorial effects of biomedical interventions. ARI Publ
34; February 2008. http://www.autism.com/treatable/form34qr.htm. Accessed May 6, 2009.
26. Levy SE, Mandell DS, Merhar S, et al. Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr. 2003;24:418-423.
27. Golnik AE, Ireland M. Complementary alternative medicine for children with autism: a physician survey.
J Autism Dev Disord. 2009;39:996-1005.
28. Liptak GS, Orlando M, Yingling JT, et al. Satisfaction with primary health care received by families of children with developmental disabilities. J Pediatr Health Care. 2006;20:245-252.
29. Kemper KJ, O’Connor KG. Pediatricians’ recommendations for complementary and alternative medical
(CAM) therapies. Ambul Pediatr. 2004;4:482-487.
30. Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics. 2007;120:1162-1182.
31. Muskiet FA, Kemperman RF. Folate and long-chain polyunsaturated fatty acids in psychiatric disease. J Nutr Biochem. 2006;17:717-727.
32. Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr. 2000;71:1669S-1675S.
33. Lakhan SE, Vieira KF. Nutritional therapies for mental health disorders. Nutr J. 2008;7:2.
34. Carlton RM, Ente G, Blum L, et al. Rational dosages of nutrients have a prolonged effect on learning disabilities. Altern Ther Health Med. 2000;6:85-91.
35. Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet. 1988;1:140-143.
36. Osendarp SJ, Baghurst KI, Bryan J, et al. Effect of a 12-mo micronutrient intervention on learning and
memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebocontrolled studies in Australia and Indonesia. Am J Clin Nutr. 2007;86:1082-1093.
37. Haskell CF, Scholey AB, Jackson PA, et al. Cognitive and mood effects in healthy children during 12 weeks’ supplementation with multi-vitamin/minerals. Br J Nutr. 2008;100:1086-1096.
38. MacLellan D, Taylor J, Wood K. Food intake and academic performance among adolescents. Can J Diet Pract Res. 2008;69:141-144.
39. Schreck KA, Williams K, Smith AF. A comparison of eating behaviors between children with and without
autism. J Autism Dev Disord. 2004;34:433-438.
40. Herndon AC, DiGuiseppi C, Johnson SL, et al. Does nutritional intake differ between children with autism spectrum disorders and children with typical development? J Autism Dev Disord. 2009;39:212-222.
41. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:851-876.
42. Tsaluchidu S, Cocchi M, Tonello L, et al. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry. 2008;8(suppl 1):S5.
43. Yorbik O, Sayal A, Akay C, et al. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:341-343.
44. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006;141:947-956.
45. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired
methylation capacity in children with autism. Am J Clin Nutr. 2004;80:1611-1617.
46. Chauhan A, Chauhan V, Brown WT, et al. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin— the antioxidant proteins. Life Sci. 2004;75:2539-2549.
47. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13:171-181.
48. Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs. 2005;65:1493-1520.
49. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev
Psychiatry. 2005;17:485-495.
50. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67-81.
51. Chez MG, Dowling T, Patel PB, et al. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007;36:361-365.
52. Connolly AM, Chez MG, Pestronk A, et al. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999;134: 607-613.
53. Connolly AM, Chez M, Streif EM, et al. Brainderived neurotrophic factor and autoantibodies to neural
antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry. 2006;59:354-363.
54. Torrente F, Ashwood P, Day R, et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry. 2002;7:375-382, 334.
55. Furlano RI, Anthony A, Day R, et al. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr. 2001;138:366-372.
56. Ashwood P, Anthony A, Pellicer AA, et al. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol. 2003;23:504-517.
57. Balzola F, Daniela C, Repici A, et al. Autistic enterocolitis: confirmation of a new inflammatory bowel disease in an Italian cohort of patients. Gastroenterology. 2005;128:A303.
58. Horvath K, Papadimitriou JC, Rabsztyn A, et al. Gastrointestinal abnormalities in children with autistic
disorder. J Pediatr. 1999;135:559-563.
59. Valicenti-McDermott M, McVicar K, Rapin I, et al. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 2006;27:S128-S136.
60. Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002;4:251-258.
61. Finegold SM, Molitoris D, Song Y, et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis. 2002;35:S6-S16.
62. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70:6459-6465.
63. Parracho HM, Bingham MO, Gibson GR, et al. Differences between the gut microflora of children with
autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005;54:987-991.
64. Jyonouchi H, Geng L, Ruby A, et al. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr. 2005;146:605-610.
65. Buie TM. Gastroesophageal reflux in children with autism: how do children present and can one test these children? J Pediatr Gastroenterol Nutr. 2005;41:505.
66. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev.
67. Nir I, Meir D, Zilber N, et al. Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord. 1995;25:641-654.
68. Kulman G, Lissoni P, Rovelli F, et al. Evidence of pineal endocrine hypofunction in autistic children. Neuro Endocrinol Lett. 2000;21:31-34.
69. Tordjman S, Anderson GM, Pichard N, et al. Nocturnal excretion of 6-sulphatoxymelatonin in children
and adolescents with autistic disorder. Biol Psychiatry. 2005;57:134-138.
70. Melke J, Goubran Botros H, Chaste P, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13:90-98.
71. Jan JE, O’Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res.
72. Hayashi E. Effect of melatonin on sleep-wake rhythm: the sleep diary of an autistic male. Psychiatry
Clin Neurosci. 2000;54:383-384.
73. Ishizaki A, Sugama M, Takeuchi N. [Usefulness of melatonin for developmental sleep and emotional/behavior disorders—studies of melatonin trial on 50 patients with developmental disorders] [In Japanese]. No To Hattatsu. 1999;31:428-437.
74. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, et al. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol. 2003;13:83-95.
75. Giannotti F, Cortesi F, Cerquiglini A, et al. An openlabel study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006;36:741-752.
76. Andersen IM, Kaczmarska J, McGrew SG, et al. Melatonin for insomnia in children with autism spectrum
disorders. J Child Neurol. 2008;23:482-485.
77. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57-64.
78. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32: 585-589.
79. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5:145-150.
80. Filipek PA, Juranek J, Nguyen MT, et al. Relative carnitine deficiency in autism. J Autism Dev Disord.
81. Ellaway CJ, Peat J, Williams K, et al. Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev. 2001;23 suppl 1:S85-S89.
82. Ellaway C, Williams K, Leonard H, et al. Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol. 1999;14:162-167.
83. Tani Y, Fernell E, Watanabe Y, et al. Decrease in 6R- 5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett. 1994;181:169-172.
84. Komori H, Matsuishi T, Yamada S, et al. Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism. J Autism Dev Disord. 1995;25:183-193.
85. Nagahata M, Kazamaturi H, Nuruse H, et al. Clinical evaluation of apropterin hydrochloride (R-THBP) on
infantile autism: a multicenter cooperative study. In: Naruse H, Ornitz EM, eds. Neurobiology of infantile autism. Proceedings of the International Symposium on Neurobiology of Infantile Autism; Nov 10-11, 1990; Tokyo, Japan. Amsterdam: Elsevier Science Ltd; 1992: 351-354.
86. Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahydrobiopterin treatment in six
children with autism—clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol.
87. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol. 2005;25:485-489.
88. Nakane Y, Naruse H, Takesada M, et al. Clinical effect of R-THBP on infantile autism. In: Naruse H, Ornitz EM, eds. Neurobiology of infantile autism. Proceedings of the International Symposium on Neurobiology of Infantile Autism; Nov 10-11, 1990; Tokyo, Japan. Amsterdam: Elsevier Science Ltd; 1992: 337-350.
89. Monks G, Juracek L, Weigand D, et al. A case of scurvy in an autistic boy. J Drugs Dermatol. 2002;1:67-69.
90. Duggan CP, Westra SJ, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 23-2007. A 9-year-old boy with bone pain, rash, and gingival hypertrophy. N Engl J Med. 2007;357:392-400.
91. Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for
autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:765-774.
92. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine
supplementation in children with autistic spectrum disorders. J Child Neurol. 2002;17:833-837.
93. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children
with autistic spectrum disorder. J Altern Complement Med. 2004;10:1033-1039.
94. Paczynski M. Piracetam: a novel therapy for autism? J Autism Dev Disord. 1997;27:628-630.
95. Akhondzadeh S, Tajdar H, Mohammadi MR, et al. A double-blind placebo controlled trial of piracetam
added to risperidone in patients with autistic disorder.
Child Psychiatry Hum Dev. 2008;39:237-245.
96. Richardson AJ, Calvin CM, Clisby C, et al. Fatty acid deficiency signs predict the severity of reading and related difficulties in dyslexic children. Prostaglandins Leukot Essent Fatty Acids. 2000;63:69-74.
97. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006;18:155-172.
98. Richardson AJ. Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. Lipids. 2004;39:1215-1222.
99. Stevens LJ, Zentall SS, Abate ML, et al. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav. 1996;59:915-920.
100. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001;65:1-7.
101. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase A2 in autistic spectrum
disorders. Prostaglandins Leukot Essent Fatty Acids. 2004;71:201-204.
102. Sliwinski S, Croonenberghs J, Christophe A, et al. Polyunsaturated fatty acids: do they have a role in the pathophysiology of autism? Neuro Endocrinol Lett. 2006;27:465-471.
103. Schultz ST, Klonoff-Cohen HS, Wingard DL, et al. Breastfeeding, infant formula supplementation, and autistic disorder: the results of a parent survey. Int Breastfeed J. 2006;1:16.
104. Johnson SM, Hollander E. Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry. 2003;64:848-849.
105. Patrick L, Salik R. The effect of essential fatty acid supplementation on language development and learning skills in autism and Asperger’s syndrome. Autism Asperger’s Digest. 2005;Jan/Feb:36-37.
106. Politi P, Cena H, Comelli M, et al. Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res. 2008;39:682-685.
107. Meguid NA, Atta HM, Gouda AS, et al. Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem. 2008;41:1044-1048.
108. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551-553.
109. Bent S, Bertoglio K, Hendren RL. Omega-3 fatty acids for autistic spectrum disorder: a systematic review. J Autism Dev Disord. 2009; 39:1145-1154.
110. Adams JB, George F, Audhya T. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Altern Complement Med. 2006;12:59-63.
111. Strambi M, Longini M, Hayek J, et al. Magnesium profile in autism. Biol Trace Elem Res. 2006;109:97-104.
112. Bonish VE. Experiences with vitamin B6 with braindamaged children with autistic syndrome. Proxis der Kinderpsychologie. 1968;8:308-310.
113. Rimland B. An orthomolecular study of psychotic children. Orthomolecular Psychiatry. 1974;3:371-377.
114. Barthelemy C, Martineau J, Bruneau N, et al. [Clinical (behavior scale items), electrophysiologic (conditioned evoked potentials) and biochemical (urinary homovanillic acid) markers in infantile autism] [In French]. Encephale. 1985;11:101-106.
115. Lelord G, Callaway E, Muh JP, et al. [Modifications in urinary homovanillic acid after ingestion of vitamin B6; functional study in autistic children (author’s transl)] [In French]. Rev Neurol (Paris). 1978;134:797-801.
116. Martineau J, Garreau B, Barthelemy C, et al. Effects of vitamin B6 on averaged evoked potentials in infantile autism. Biol Psychiatry. 1981;16:627-641.
117. Martineau J, Barthelemy C, Cheliakine C, et al. Brief report: an open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988;18:435-447.
118. Martineau J, Barthelemy C, Roux S, et al. Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour. Dev Med Child Neurol. 1989;31:721-727.
119. Menage P, Thibault G, Barthelemy C, et al. CD 4+CD 45 RA+ T lymphocyte deficiency in autistic children: effect of a pyridoxine-magnesium treatment. Brain Dysfunct. 1992;5:326-333.
120. Barthelemy C, Garreau B, Leddet I, et al. [Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism (author’s transl)] [In French]. Therapie. 1980;35:627-632.
121. Barthelemy C, Garreau B, Leddet I. Behavioral and biological effects of oral magnesium, vitamin B6 and combined magnesium–vitamin B6 administration in autistic children. Magnes Bull. 1981;2:150-153.
122. Jonas C, Etienne T, Barthelemy C, et al. [Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults] [In French]. Therapie. 1984;39:661-669.
123. Martineau J, Barthelemy C, Garreau B, et al. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry. 1985;20:467-478.
124. Lelord G, Muh JP, Barthelemy C, et al. Effects of pyridoxine and magnesium on autistic symptoms—initial observations. J Autism Dev Disord. 1981;11:219-230.
125. Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4:27-44.
126. Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry. 1978;135:472-475.
127. Tolbert L, Haigler T, Waits MM, et al. Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord. 1993;23:193-199.
128. Findling RL, Maxwell K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium administration
in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord. 1997;27:467-478.
129. Kuriyama S, Kamiyama M, Watanabe M, et al. Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Dev Med Child Neurol. 2002;44:284-286.
130. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev. 2005;(4):CD003497.
131. Mousain-Bosc M, Roche M, Polge A, et al. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res. 2006;19:53-62.
132. McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics. 2000;105:E18.
133. Wakefield AJ, Murch SH, Anthony A, et al. Ileallymphoid-nodular hyperplasia, non-specific colitis, and
pervasive developmental disorder in children. Lancet. 1998;351:637-641.
134. Lowe TL, Cohen DJ, Miller S, et al. Folic acid and B12 in autism and neuropsychiatric disturbances of childhood. J Am Acad Child Psychiatry. 1981;20:104-111.
135. Gillberg C, Wahlstrom J, Johansson R, et al. Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol. 1986;28:624-627.
136. Nakano K, Noda N, Tachikawa E, et al. A preliminary study of methylcobalamin therapy in autism. Journal of Tokyo Women’s Medical University. 2005;75:64-69.
137. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr. 2009;89:1-6.
138. Moretti P, Peters SU, Del Gaudio D, et al. Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. J Autism Dev Disord. 2008;38:1170-1177.
139. Moretti P, Sahoo T, Hyland K, et al. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology. 2005;64:1088-1090.
140. Ramaekers VT, Blau N, Sequeira JM, et al. Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics. 2007;38:276-281.
141. Ramaekers VT, Sequeira JM, Blau N, et al. A milkfree diet downregulates folate receptor autoimmunity
in cerebral folate deficiency syndrome. Dev Med Child Neurol. 2008;50:346-352.
142. Niederhofer H. First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder. Phytother Res. 2009 Mar 9. [E-pub ahead of print.]
143. Levine J, Aviram A, Holan A, et al. Inositol treatment of autism. J Neural Transm. 1997;104:307-310.
144. Lozoff B, Beard J, Connor J, et al. Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr Rev. 2006;64:S34-43; discussion S72-91.
145. Halterman JS, Kaczorowski JM, Aligne CA, et al. Iron deficiency and cognitive achievement among schoolaged children and adolescents in the United States. Pediatrics. 2001;107:1381-1386.
146. Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348:992-996.
147. Latif A, Heinz P, Cook R. Iron deficiency in autism and Asperger syndrome. Autism. 2002;6:103-114.
148. Dosman CF, Drmic IE, Brian JA, et al. Ferritin as an indicator of suspected iron deficiency in children
with autism spectrum disorder: prevalence of low serum ferritin concentration. Dev Med Child Neurol.
149. Cornish E. A balanced approach towards healthy eating in autism. Journal of Human Nutrition and Dietetics. 1998;11:501-509.
150. Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol. 2007;36:152-158.
151. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressiveonset autism. J Child Neurol. 2000;15:429-435.
152. Brudnak MA, Rimland B, Kerry RE, et al. Enzymebased therapy for autism spectrum disorders—is it
worth another look? Med Hypotheses. 2002;58:422-428.
153. Brudnak MA. Probiotics as an adjuvant to detoxification protocols. Med Hypotheses. 2002;58:382-385.
154. Blades M. Autism: an interesting dietary case history. Nutrition and Food Science. 2000;30:137-140.
155. Niederhofer H. St John’s Wort treating patients with autistic disorder. Phytother Res. 2009;Mar 9[Epub ahead of print].
156. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999;29:191-194.
157. Kern JK, Miller VS, Cauller PL, et al. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16:169-173.
158. McDougle CJ, Naylor ST, Cohen DJ, et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53:993-1000.
159. Sverd J, Kupietz SS, Winsberg BG, et al. Effects of L-5-hydroxytryptophan in autistic children. J Autism Child Schizophr. 1978;8:171-180.
160. Cannell JJ. Autism and vitamin D. Med Hypotheses. 2008;70:750-759.
161. Stewart C, Latif A. Symptomatic nutritional rickets in a teenager with autistic spectrum disorder. Child Care Health Dev. 2008;34:276-278.
162. Clark JH, Rhoden DK, Turner DS. Symptomatic vitamin A and D deficiencies in an eight-year-old with
autism. JPEN J Parenter Enteral Nutr. 1993;17:284-286.
163. Steinemann TL, Christiansen SP. Vitamin A deficiency and xerophthalmia in an autistic child. Arch
Ophthalmol. 1998;116:392-393.
164. Uyanik O, Dogangun B, Kayaalp L, et al. Food faddism causing vision loss in an autistic child. Child Care Health Dev. 2006;32:601-602.
165. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses.
166. Shaywitz BA, Siegel NJ, Pearson HA. Megavitamins for minimal brain dysfunction. A potentially dangerous therapy. JAMA. 1977;238:1749-1750.
167. Kimmoun A, Leheup B, Feillet F, et al. [Hypercalcemia revealing iatrogenic hypervitaminosis A in a
child with autistic troubles] [In French]. Arch Pediatr. 2008;15:29-32.
168. Jory J, McGinnis WR. Red-cell trace minerals in children with autism. Am J Biochem Biotech. 2008;4:101- 104.
169. Pfeiffer CC, Braverman ER. Zinc, the brain and behavior. Biol Psychiatry. 1982;17:513-532.
170. Yorbik O, Olgun A, Kirmizigul P, et al. [Plasma zinc and copper levels in boys with oppositional defiant disorder] [In Turkish]. Turk Psikiyatri Derg. 2004;15:276-281.
171. Jackson MJ, Garrod PJ. Plasma zinc, copper, and amino acid levels in the blood of autistic children. J Autism Child Schizophr. 1978;8:203-208.
172. Yorbik O, Akay C, Sayal A, et al. Zinc status in autistic children. J Trace Elem Exp Med. 2004;17:101-107.
173. Panksepp J. A neurochemical theory of autism. Trends Neurosci. 1979;2:174-177.
174. Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol. 2002;129:168-177.
175. Vojdani A, Pangborn JB, Vojdani E, et al. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol. 2003;16:189-199.
176. Vojdani A, O’Bryan T, Green JA, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci. 2004;7:151-161.
177. Vojdani A, Bazargan M, Vojdani E, et al. Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. Clin Diagn Lab Immunol. 2004;11:515-524.
178. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine
production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46:76-84.
179. Ashwood P, Anthony A, Torrente F, et al. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin- 10. J Clin Immunol. 2004;24:664-673.
180. Afzal N, Murch S, Thirrupathy K, et al. Constipation with acquired megarectum in children with autism. Pediatrics. 2003;112:939-942.
181. Barcia G, Posar A, Santucci M, et al. Autism and coeliac disease. J Autism Dev Disord. 2008;38:407-408.
182. Lucarelli S, Frediani T, Zingoni AM, et al. Food allergy and infantile autism. Panminerva Med. 1995;37:137-141.
183. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003;18:113-118.
184. O’Banion D, Armstrong B, Cummings RA, et al. Disruptive behavior: a dietary approach. J Autism Child Schizophr. 1978;8:325-337.
185. Sponheim E. [Gluten-free diet in infantile autism. A therapeutic trial] [In Norwegian]. Tidsskr Nor Laegeforen. 1991;111:704-707.
186. Reichelt KL, Ekrem J, Scott H. Gluten, milk proteins and autism: dietary intervention effects on behavior and peptide secretion. J Appl Nutr. 1990;42:1-11.
187. Knivsberg AM, Wiig K, Lind G, et al. Dietary intervention in autistic syndromes. Brain Dysfunction.
188. Knivsberg AM, Reichelt KL, Nodland M, et al. Autistic symptoms and diet: a follow-up study. Scand J Ed Research. 1995;39:223-236.
189. Whiteley P, Rodgers J, Savery D, et al. A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism. 1999;3:45.
190. Cade R, Privette M, Fregly M, et al. Autism and schizophrenia: intestinal disorders. Nutritional Neuroscience. 2000;3:57-72.
191. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff? J Dev Behav Pediatr. 2006;27:S162-S171.
192. Goin-Kochel RP, Mackintosh VH, Myers BJ. Parental reports on the efficacy of treatments and therapies for their children with autism spectrum disorders. Research in Autism Spectrum Disorders. 2009;3:528-537.
193. Knivsberg AM, Reichelt KL, Hoien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002;5:251-261.
194. Elder JH, Shankar M, Shuster J, et al. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006;36:413-420.
195. Millward C, Ferriter M, Calver S, et al. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev. 2008;(2):CD003498.
196. Adams SJ, Burton N, Cutress A, et al. Development of double blind gluten and casein free test foods for use in an autism dietary trial. J Hum Nutr Diet. 2008;21:374.
197. Arnold GL, Hyman SL, Mooney RA, et al. Plasma amino acids profiles in children with autism: potential
risk of nutritional deficiencies. J Autism Dev Disord. 2003;33:449-454.
198. Hediger ML, England LJ, Molloy CA, et al. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord. 2008;38:848-856.
199. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. 2001;158:1058-1066.
200. Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19:165-169.
201. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12:237-241.
202. Chez MG, Nowinski CV, Buchanan CP. Donepezil use in children with autistic spectrum disorders. Ann
Neurol. 2000;48:541.
203. Chez MG, Buchanan TM, Becker M, et al. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1:83-88.
204. Hertzman M. Galantamine in the treatment of adult autism: a report of three clinical cases. Int J Psychiatry Med. 2003;33:395-398.
205. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16:621-629.
206. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ.
207. Campbell M, Anderson LT, Small AM, et al. Naltrexone in autistic children: a double-blind and placebocontrolled study. Psychopharmacol Bull. 1990;26:130-135.
208. Leboyer M, Bouvard MP, Launay JM, et al. Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord. 1992;22:309-319.
209. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, et al. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58:203-215.
210. Bouvard MP, Leboyer M, Launay JM, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 1995;58:191-201.
211. Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry. 1995;34:223-231.
212. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry. 1996;39:1023-1031.
213. Elchaar GM, Maisch NM, Augusto LM, et al. Efficacy and safety of naltrexone use in pediatric patients
with autistic disorder. Ann Pharmacother. 2006;40:1086-1095.
214. Koshes RJ, Rock NL. Use of clonidine for behavioral control in an adult patient with autism. Am J Psychiatry. 1994;151:1714.
215. Ming X, Gordon E, Kang N, et al. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30:454-460.
216. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77-82.
217. Jaselskis CA, Cook EH Jr, Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322-327.
218. Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14:233-241.
219. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:589-598.
220. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29:303-308.
221. Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation
in children and adolescents with attention-deficithyperactivity disorder. Pharmacotherapy. 2007;27:1253-
222. Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism.
Med Hypotheses. 2007;68:1208-1227.
223. Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children.
Med Hypotheses. 2006;67:216-228.
224. Rossignol DA, Rossignol LW, James SJ, et al. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr. 2007;7:36.
225. Chungpaibulpatana J, Sumpatanarax T, Thadakul N, et al. Hyperbaric oxygen therapy in Thai autistic children. J Med Assoc Thai. 2008;91:1232-1238.
226. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009;9:21.
227. Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136:682-687.
228. Stefanatos GA, Grover W, Geller E. Case study: corticosteroid treatment of language regression in pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:1107-1111.
229. Chez MG, Loeffel M, Buchanan C, et al. Pulse high dose steroids as combination therapy with valproic acid in epileptic aphasia patients with pervasive developmental delay or autism. Ann Neurol. 1998;44:539.
230. Buitelaar JK, van Engeland H, de Kogel K, et al. The adrenocorticotrophic hormone (4-9) analog ORG
2766 benefits autistic children: report on a second controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 1992;31:1149-1156.
231. Buitelaar JK, van Engeland H, de Kogel KH, et al. The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biol Psychiatry. 1992;31:1119-1129.
232. Buitelaar JK, van Engeland H, van Ree JM, et al. Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4-9), in 14 outpatient autistic children. J Autism Dev Disord. 1990;20:467-478.
233. Boris M, Kaiser CC, Goldblatt A, et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation. 2007;4:3.
234. Bradstreet JJ, Smith S, Granpeesheh D, et al. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med Hypotheses. 2007;68:979-987.
235. Gupta S, Rimland B, Shilling PD. Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. J Child Neurol. 1996;11:501-504.
236. Heuer L, Ashwood P, Schauer J, et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res. 2008;1:275-283.
237. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996;26:439-452.
238. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13:79-82.
239. Gupta S. Immunological treatments for autism. J Autism Dev Disord. 2000;30:475-479.
240. DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999;29:157-160.
241. Plioplys AV. Intravenous immunoglobulin treatment in autism. J Autism Dev Disord. 2000;30:73-74.
242. Boris M, Goldblatt A, Edelson SM. Improvement in children with autism treated with intravenous gamma globulin. J Nutritional Environmental Medicine. 2005;15:169-176.
243. Schneider CK, Melmed RD, Barstow LE, et al. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. J Autism Dev Disord. 2006;36:1053-1064.
244. Handen BL, Melmed RD, Hansen RL, et al. A doubleblind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord. 2009;39:796-805.
245. Stubbs EG, Budden SS, Burger DR, et al. Transfer factor immunotherapy of an autistic child with congenital cytomegalovirus. J Autism Dev Disord. 1980;10:451-458.
246. Fudenberg HH. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy. 1996;9:143-147.
247. Bartz JA, Hollander E. Oxytocin and experimental therapeutics in autism spectrum disorders. Prog Brain Res. 2008;170:451-462.
248. Lerer E, Levi S, Salomon S, et al. Association between the oxytocin receptor (OXTR) gene and autism:
relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry. 2008;13:980-988.
249. Wu S, Jia M, Ruan Y, et al. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry. 2005;58:74-77.
250. Jacob S, Brune CW, Carter CS, et al. Association of the oxytocin receptor gene (OXTR) in Caucasian
children and adolescents with autism. Neurosci Lett. 2007;417:6-9.
251. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry. 1998;43:270- 277.
252. Domes G, Heinrichs M, Michel A, et al. Oxytocin improves “mind-reading” in humans. Biol Psychiatry.
253. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology. 2003;28:193-198.
254. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61:498-503.
255. Cohen DJ, Johnson WT, Caparulo BK. Pica and elevated blood lead level in autistic and atypical children. Am J Dis Child. 1976;130:47-48.
256. Accardo P, Whitman B, Caul J, et al. Autism and plumbism. A possible association. Clin Pediatr (Phila).
257. Eppright TD, Sanfacon JA, Horwitz EA. Attention deficit hyperactivity disorder, infantile autism, and elevated blood-lead: a possible relationship. Mo Med. 1996;93:136-138.
258. Lidsky TI, Schneider JS. Autism and autistic symptoms associated with childhood lead poisoning. Journal of Applied Research. 2005;5:80-87.
259. Kidd PM. Autism, an extreme challenge to integrative medicine. Part II: medical management. Alternative Medicine Review. 2002;7:472-499.
260. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002;23:303-308.
261. Geier DA, Geier MR. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic
disorders. Neuro Endocrinol Lett. 2006;27:833-838.
262. Patel K, Curtis LT. A comprehensive approach to treating autism and attention-deficit hyperactivity
disorder: a prepilot study. J Altern Complement Med. 2007;13:1091-1097.
263. Nataf R, Skorupka C, Amet L, et al. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol. 2006;214:99-108.
264. Bradstreet JJ, Geier DA, Kartzinel JJ, et al. A casecontrol study of mercury burden in children with autistic spectrum disorders. Journal of American Physicians and Surgeons. 2003;8:76-79.
265. Soden SE, Lowry JA, Garrison CB, et al. 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila). 2007;45:476-481.
266. Shannon M, Graef JW. Lead intoxication in children with pervasive developmental disorders. J Toxicol Clin Toxicol. 1996;34:177-181.
267. Geier DA, Geier MR. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox Res. 2006;10:57-64.
268. Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders.
J Toxicol Environ Health A. 2007;70:1723-1730.
269. Van der Linde AA, Pillen S, Gerrits GP, et al. Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy. Clin Toxicol (Phila). 2008;46:479-481.
270. Brown MJ, Willis T, Omalu B, et al. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006;118:e534-536.
271. Chen ZK, Lu ZQ. Sodium dimercaptopropane sulfonate as antidote against non-metallic pesticides. Acta Pharmacol Sin. 2004;25:534-544.
272. Flora SJ, Pande M, Mehta A. Beneficial effect of combined administration of some naturally occurring
antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication. Chem Biol Interact.
273. Flora SJ, Flora G, Saxena G, et al. Arsenic and lead induced free radical generation and their reversibility following chelation. Cell Mol Biol (Noisy-le-grand). 2007;53:26-47.
274. Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344:1421-1426.
275. Dietrich KN, Ware JH, Salganik M, et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004;114:19-26.
276. Bhattacharya A, Shukla R, Auyang ED, et al. Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead. Neurotoxicology. 2007;28:686-695.
277. Mitka M. Chelation therapy trials halted. JAMA. 2008;300:2236.
278. Gudarzi SS, Yasamy M, Akhondzadeh S. Cyproheptadine in treatment of autism. Eur Psychiatry. 2002;17:230-231.
279. Akhondzadeh S, Erfani S, Mohammadi MR, et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther. 2004;29:145-150.
280. Linday LA. Oral famotidine: a potential treatment for children with autism. Med Hypotheses. 1997;48:381-386.
281. Linday LA, Tsiouris JA, Cohen IL, et al. Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design. J Neural Transm. 2001;108:593-611.
282. Purcell AE, Jeon OH, Zimmerman AW, et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001;57:1618-1628.
283. Moreno-Fuenmayor H, Borjas L, Arrieta A, et al. Plasma excitatory amino acids in autism. Invest Clin.
284. Erickson CA, Chambers JE. Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry.
285. Erickson CA, Posey DJ, Stigler KA, et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191:141-147.
286. Owley T, Salt J, Guter S, et al. A prospective, openlabel trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:517-524.
287. Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22:574-579.
288. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics. 1993;24:339-340.
289. Mendhekar DN, Duggal HS. Acquired variant of Rett’s disorder and response to lamotrigine. J Neuropsychiatry Clin Neurosci. 2007;19:474-475.
290. Kumandas S, Caksen H, Ciftci A, et al. Lamotrigine in two cases of Rett syndrome. Brain Dev. 2001;23:240-242.
291. Stenbom Y, Tonnby B, Hagberg B. Lamotrigine in Rett syndrome: treatment experience from a pilot study. Eur Child Adolesc Psychiatry. 1998;7:49-52.
292. Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics. 1994;25:284-289.
293. Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, doubleblind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175-181.
294. Posey DJ, Kem DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161:2115-2117.
295. Sturmey P. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res Dev Disabil. 2005;26:87-97.
296. Esch BE, Carr JE. Secretin as a treatment for autism: a review of the evidence. J Autism Dev Disord.
297. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005;(3):CD003495.
298. Ratliff-Schaub K, Carey T, Reeves GD, et al. Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism. 2005;9:256-265.
299. Boso M, Emanuele E, Minazzi V, et al. Effect of longterm interactive music therapy on behavior profile and musical skills in young adults with severe autism. J Altern Complement Med. 2007;13:709-712.
300. Kern P, Aldridge D. Using embedded music therapy interventions to support outdoor play of young children with autism in an inclusive community-based child care program. J Music Ther. 2006;43:270-294.
301. Kim J, Wigram T, Gold C. The effects of improvisational music therapy on joint attention behaviors in autistic children: a randomized controlled study. J Autism Dev Disord. 2008;38:1758-1766.
302. Corbett BA, Shickman K, Ferrer E. Brief report: the effects of Tomatis sound therapy on language in children with autism. J Autism Dev Disord. 2008;38:562-566.
303. Whipple J. Music in intervention for children and adolescents with autism: a meta-analysis. J Music Ther. 2004;41:90-106.
304. Gold C, Wigram T, Elefant C. Music therapy for autistic spectrum disorder. Cochrane Database Syst Rev. 2006;(2):CD004381.
305. Kaplan M, Carmody DP, Gaydos A. Postural orientation modifications in autism in response to ambient
lenses. Child Psychiatry Hum Dev. 1996;27:81-91.
306. Kaplan M, Edelson SM, Seip JA. Behavioral changes in autistic individuals as a result of wearing ambient transitional prism lenses. Child Psychiatry Hum Dev. 1998;29:65-76.
307. Chen WX, Wu-Li L, Wong VC. Electroacupuncture for children with autism spectrum disorder: pilot study of 2 cases. J Altern Complement Med. 2008;14:1057-1065.
308. Allam H, ElDine NG, Helmy G. Scalp acupuncture effect on language development in children with autism: a pilot study. J Altern Complement Med. 2008;14:109-114.
309. Rimland B, Edelson SM. Brief report: a pilot study of auditory integration training in autism. J Autism Dev Disord. 1995;25:61-70.
310. Sinha Y, Silove N, Wheeler D, et al. Auditory integration training and other sound therapies for autism
spectrum disorders: a systematic review. Arch Dis Child. 2006;91:1018-1022.
311. Cullen-Powell LA, Barlow JH, Cushway D. Exploring a massage intervention for parents and their children with autism: the implications for bonding and attachment. J Child Health Care. 2005;9:245-255.
312. Williams TI. Evaluating effects of aromatherapy massage on sleep in children with autism: a pilot study. Evid Based Complement Alternat Med. 2006;3:373-377.
313. Escalona A, Field T, Singer-Strunck R, et al. Brief report: improvements in the behavior of children with autism following massage therapy. J Autism Dev Disord. 2001;31:513-516.
314. Silva LM, Cignolini A. A medical qigong methodology for early intervention in autism spectrum disorder: a case series. Am J Chin Med. 2005;33:315-327.
315. Silva LM, Ayres R, Schalock M. Outcomes of a pilot training program in a qigong massage intervention
for young children with autism. Am J Occup Ther. 2008;62:538-546.
316. Silva LM, Cignolini A, Warren R, et al. Improvement in sensory impairment and social interaction in
young children with autism following treatment with an original Qigong massage methodology. Am J Chin Med. 2007;35:393-406.
317. Jarusiewicz B. Efficacy of neurofeedback for children in the autism spectrum: a pilot study. J Neurotherapy. 2002;6:39-49.
318. Robinson TW. Homeopathic secretin in autism: a clinical pilot study. British Homeopathic Journal.
319. Warwick TC, Griffith J, Reyes B, et al. Effects of vagus nerve stimulation in a patient with temporal lobe epilepsy and Asperger syndrome: case report and review of the literature. Epilepsy Behav. 2007;10:344-347.
320. Park YD. The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism. Epilepsy Behav. 2003;4:286-290.
321. Danielsson S, Viggedal G, Gillberg C, et al. Lack of effects of vagus nerve stimulation on drug-resistant epilepsy in eight pediatric patients with autism spectrum disorders: a prospective 2-year follow-up study. Epilepsy Behav. 2008;12:298-304.